MARATTO

article · OALib

Effective Treatment of Epirubicin Extravasation with Dexrazoxane: A Case Report of Positive Clinical Outcomes

Abstract

Accidental extravasation of anthracyclines is a rare incident but if ever it happens, it can lead to serious complications, which could go as far as tissue necrosis with the need for surgery in most of the cases. In accordance with current recommendations, intravenous administration of Dexrazoxane within 6 hours of extravasation is recommended to reduce the risk of skin necrosis. We report the case of a 63-year-old patient, diagnosed with breast cancer, who presented with extravasation of Epirubicin, during her first cycle of adjuvant chemotherapy, with a favorable evolution after being treated with Dexrazoxane.

Research topics

  • Chemotherapy-related skin toxicity
  • Cancer Treatment and Pharmacology
  • Vascular Tumors and Angiosarcomas

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.4236/oalib.1110361

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.